vs
达尔科技（DIOD）与ROGERS CORP（ROG）财务数据对比。点击上方公司名可切换其他公司
达尔科技的季度营收约是ROGERS CORP的2.0倍（$391.6M vs $200.5M），达尔科技净利率更高（2.6% vs 2.2%，领先0.4%），达尔科技同比增速更快（15.4% vs 5.2%），达尔科技自由现金流更多（$12.4M vs $1.1M），过去两年达尔科技的营收复合增速更高（13.9% vs -3.3%）
达尔科技是一家全球性半导体制造商，主营分立器件、模拟及混合信号半导体产品的设计、生产与销售，产品广泛应用于汽车、工业、消费电子、计算及通信基础设施等核心领域，服务全球各地客户。
罗杰斯公司是一家专注于特种工程材料研发生产的企业，总部位于美国亚利桑那州钱德勒市，其产品广泛应用于先进电子、移动通信、清洁能源、航空航天等多个高科技领域，为全球客户提供高性能材料解决方案。
DIOD vs ROG — 直观对比
营收规模更大
DIOD
是对方的2.0倍
$200.5M
营收增速更快
DIOD
高出10.2%
5.2%
净利率更高
DIOD
高出0.4%
2.2%
自由现金流更多
DIOD
多$11.3M
$1.1M
两年增速更快
DIOD
近两年复合增速
-3.3%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $391.6M | $200.5M |
| 净利润 | $10.2M | $4.5M |
| 毛利率 | 31.1% | 32.2% |
| 营业利润率 | 3.4% | — |
| 净利率 | 2.6% | 2.2% |
| 营收同比 | 15.4% | 5.2% |
| 净利润同比 | 23.8% | 421.4% |
| 每股收益（稀释后） | $0.23 | $0.25 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DIODROG
| Q1 26 | — | $200.5M | ||
| Q4 25 | $391.6M | $201.5M | ||
| Q3 25 | $392.2M | $216.0M | ||
| Q2 25 | $366.2M | $202.8M | ||
| Q1 25 | $332.1M | $190.5M | ||
| Q4 24 | $339.3M | $192.2M | ||
| Q3 24 | $350.1M | $210.3M | ||
| Q2 24 | $319.8M | $214.2M |
净利润DIODROG
| Q1 26 | — | $4.5M | ||
| Q4 25 | $10.2M | $4.6M | ||
| Q3 25 | $14.3M | $8.6M | ||
| Q2 25 | $46.1M | $-73.6M | ||
| Q1 25 | $-4.4M | $-1.4M | ||
| Q4 24 | $8.2M | $-500.0K | ||
| Q3 24 | $13.7M | $10.7M | ||
| Q2 24 | $8.0M | $8.1M |
毛利率DIODROG
| Q1 26 | — | 32.2% | ||
| Q4 25 | 31.1% | 31.5% | ||
| Q3 25 | 30.7% | 33.5% | ||
| Q2 25 | 31.5% | 31.6% | ||
| Q1 25 | 31.5% | 29.9% | ||
| Q4 24 | 32.7% | 32.1% | ||
| Q3 24 | 33.7% | 35.2% | ||
| Q2 24 | 33.6% | 34.1% |
营业利润率DIODROG
| Q1 26 | — | — | ||
| Q4 25 | 3.4% | 3.5% | ||
| Q3 25 | 3.0% | 7.3% | ||
| Q2 25 | 2.6% | -33.3% | ||
| Q1 25 | 0.4% | -0.2% | ||
| Q4 24 | 3.5% | -6.6% | ||
| Q3 24 | 6.2% | 6.9% | ||
| Q2 24 | 1.2% | 5.3% |
净利率DIODROG
| Q1 26 | — | 2.2% | ||
| Q4 25 | 2.6% | 2.3% | ||
| Q3 25 | 3.6% | 4.0% | ||
| Q2 25 | 12.6% | -36.3% | ||
| Q1 25 | -1.3% | -0.7% | ||
| Q4 24 | 2.4% | -0.3% | ||
| Q3 24 | 3.9% | 5.1% | ||
| Q2 24 | 2.5% | 3.8% |
每股收益（稀释后）DIODROG
| Q1 26 | — | $0.25 | ||
| Q4 25 | $0.23 | $0.20 | ||
| Q3 25 | $0.31 | $0.48 | ||
| Q2 25 | $0.99 | $-4.00 | ||
| Q1 25 | $-0.10 | $-0.08 | ||
| Q4 24 | $0.18 | $-0.04 | ||
| Q3 24 | $0.30 | $0.58 | ||
| Q2 24 | $0.17 | $0.44 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $377.0M | $195.8M |
| 总债务越低越好 | $25.7M | — |
| 股东权益账面价值 | $1.9B | $1.2B |
| 总资产 | $2.4B | $1.4B |
| 负债/权益比越低杠杆越低 | 0.01× | — |
8季度趋势，按日历期对齐
现金及短期投资DIODROG
| Q1 26 | — | $195.8M | ||
| Q4 25 | $377.0M | $197.0M | ||
| Q3 25 | $386.4M | $167.8M | ||
| Q2 25 | $327.3M | $157.2M | ||
| Q1 25 | $343.9M | $175.6M | ||
| Q4 24 | $316.1M | $159.8M | ||
| Q3 24 | $319.3M | $146.4M | ||
| Q2 24 | $273.9M | $119.9M |
总债务DIODROG
| Q1 26 | — | — | ||
| Q4 25 | $25.7M | — | ||
| Q3 25 | $24.9M | — | ||
| Q2 25 | $26.4M | — | ||
| Q1 25 | $20.5M | — | ||
| Q4 24 | $20.7M | — | ||
| Q3 24 | $22.2M | — | ||
| Q2 24 | $20.3M | — |
股东权益DIODROG
| Q1 26 | — | $1.2B | ||
| Q4 25 | $1.9B | $1.2B | ||
| Q3 25 | $1.9B | $1.2B | ||
| Q2 25 | $1.9B | $1.2B | ||
| Q1 25 | $1.8B | $1.3B | ||
| Q4 24 | $1.8B | $1.3B | ||
| Q3 24 | $1.8B | $1.3B | ||
| Q2 24 | $1.8B | $1.3B |
总资产DIODROG
| Q1 26 | — | $1.4B | ||
| Q4 25 | $2.4B | $1.4B | ||
| Q3 25 | $2.5B | $1.4B | ||
| Q2 25 | $2.5B | $1.5B | ||
| Q1 25 | $2.4B | $1.5B | ||
| Q4 24 | $2.4B | $1.5B | ||
| Q3 24 | $2.4B | $1.5B | ||
| Q2 24 | $2.4B | $1.5B |
负债/权益比DIODROG
| Q1 26 | — | — | ||
| Q4 25 | 0.01× | — | ||
| Q3 25 | 0.01× | — | ||
| Q2 25 | 0.01× | — | ||
| Q1 25 | 0.01× | — | ||
| Q4 24 | 0.01× | — | ||
| Q3 24 | 0.01× | — | ||
| Q2 24 | 0.01× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $38.1M | $5.8M |
| 自由现金流经营现金流 - 资本支出 | $12.4M | $1.1M |
| 自由现金流率自由现金流/营收 | 3.2% | 0.5% |
| 资本支出强度资本支出/营收 | 6.6% | 2.3% |
| 现金转化率经营现金流/净利润 | 3.74× | 1.29× |
| 过去12个月自由现金流最近4个季度 | $137.2M | $70.1M |
8季度趋势，按日历期对齐
经营现金流DIODROG
| Q1 26 | — | $5.8M | ||
| Q4 25 | $38.1M | $46.9M | ||
| Q3 25 | $79.1M | $28.9M | ||
| Q2 25 | $41.5M | $13.7M | ||
| Q1 25 | $56.7M | $11.7M | ||
| Q4 24 | $81.8M | $33.7M | ||
| Q3 24 | $54.4M | $42.4M | ||
| Q2 24 | $14.4M | $22.9M |
自由现金流DIODROG
| Q1 26 | — | $1.1M | ||
| Q4 25 | $12.4M | $42.2M | ||
| Q3 25 | $62.8M | $21.2M | ||
| Q2 25 | $21.1M | $5.6M | ||
| Q1 25 | $40.8M | $2.1M | ||
| Q4 24 | $62.1M | $18.3M | ||
| Q3 24 | $39.4M | $25.2M | ||
| Q2 24 | $-3.5M | $8.8M |
自由现金流率DIODROG
| Q1 26 | — | 0.5% | ||
| Q4 25 | 3.2% | 20.9% | ||
| Q3 25 | 16.0% | 9.8% | ||
| Q2 25 | 5.8% | 2.8% | ||
| Q1 25 | 12.3% | 1.1% | ||
| Q4 24 | 18.3% | 9.5% | ||
| Q3 24 | 11.2% | 12.0% | ||
| Q2 24 | -1.1% | 4.1% |
资本支出强度DIODROG
| Q1 26 | — | 2.3% | ||
| Q4 25 | 6.6% | 2.3% | ||
| Q3 25 | 4.2% | 3.6% | ||
| Q2 25 | 5.6% | 4.0% | ||
| Q1 25 | 4.8% | 5.0% | ||
| Q4 24 | 5.8% | 8.0% | ||
| Q3 24 | 4.3% | 8.2% | ||
| Q2 24 | 5.6% | 6.6% |
现金转化率DIODROG
| Q1 26 | — | 1.29× | ||
| Q4 25 | 3.74× | 10.20× | ||
| Q3 25 | 5.54× | 3.36× | ||
| Q2 25 | 0.90× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 9.93× | — | ||
| Q3 24 | 3.95× | 3.96× | ||
| Q2 24 | 1.80× | 2.83× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DIOD
| Distributor | $253.1M | 65% |
| Direct Sales | $138.5M | 35% |
ROG
暂无分部数据
